3 Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette–Guerin vaccination against tuberculosis. Health Technol Assess 2013 17: 1–372. 4 Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998 2: 200–207. 5 Miner MD, Hatherill M, Mave V, et al. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV 2022 9: e791–e800. 6 WHO. WHO Preferred Product Characteristics for New Tuberculosis Vaccines. Geneva, WHO, 2018. 7 Cobelens F, Suri RK, Helinski M, et al. Accelerating research and development of new vaccines against tuberculosis: a global roadmap. Lancet Infect Dis 2022 22: e108–e120. 8 Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013 5: 205ra134. 9 Jeyanathan M, Damjanovic D, Yao Y, et al. Induction of an immune-protective T-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans. J Infect Dis 2016 214: 1996–2005. 10 Wilkie M, Satti I, Minhinnick A, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults. Vaccine 2020 38: 779–789. 11 Folegatti PM, Jenkin D, Morris S, et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: standardized template with key considerations for a risk/benefit assessment. Vaccine 2022 40: 5248–5262. 12 Buzitskaya Z, Stosman K, Khairullin B, et al. A new intranasal influenza vector-based vaccine TB/FLU-04L against tuberculosis: preclinical safety studies. Drug Res (Stuttg) 2022 72: 255–258. 13 Luabeya AK, Kagina BM, Tameris MD, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 2015 33: 4130–4140. 14 Bekker LG, Dintwe O, Fiore-Gartland A, et al. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine 2020 21: 100313. 15 Suliman S, Luabeya AKK, Geldenhuys H, et al. Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med 2019 199: 220–231. 16 Jenum S, Tonby K, Rueegg CS, et al. A phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nat Commun 2021 12: 6774. 17 Penn-Nicholson A, Tameris M, Smit E, et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 +GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 2018 6: 287–298. 18 Day TA, Penn-Nicholson A, Luabeya AKK, et al. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 +GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med 2021 9: 373–386. 19 Day CL, Tameris M, Mansoor N, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013 188: 492–502. 20 Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 2015 33: 4025–4034. 21 van der Meeren O, Hatherill M, Nduba V, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 2018 379: 1621–1634. 22 Tait DR, Hatherill M, van der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 2019 381: 2429–2439. 23 Vasina DV, Kleymenov DA, Manuylov VA, et al. First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment. Vaccines (Basel) 2019 7: 166. 24 Tkachuk AP, Bykonia EN, Popova LI, et al. Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines (Basel) 2020 8: 652. 25 Chen L, Xu M, Wang ZY, et al. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunol Med Microbiol 2010 59: 42–52. 26 Sharma SK, Katoch K, Sarin R, et al. Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci Rep 2017 7: 3354. 27 Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014 371: 1121–1130. 174 https://doi.org/10.1183/2312508X.10024922 ERS MONOGRAPH |THE CHALLENGE OF TB IN THE 21ST CENTURY